Poseida Therapeutics Announces Participation in Stifel's 2024 Virtual Cell Therapy Forum
Poseida Therapeutics Announces Participation in Stifel's 2024 Virtual Cell Therapy Forum
SAN DIEGO, July 1, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer and rare diseases, today announced that the Company's President and Chief Executive Officer, Kristin Yarema, Ph.D., will participate in a virtual fireside chat at the Stifel 2024 Virtual Cell Therapy Forum on Tuesday, July 9, 2024 at 7:55am PT | 10:55am ET.
聖地亞哥，2024年7月1日 /PRNewswire/ — Poseida Therapeutics, Inc.（納斯達克股票代碼：PSTX）是一家臨床階段的異體細胞療法和基因藥物公司，致力於爲癌症和罕見疾病患者提供差異化非病毒治療，今天宣佈，該公司總裁兼首席執行官克里斯汀·亞雷瑪博士將參加Stifel 2024虛擬細胞療法的虛擬爐邊談話論壇將於太平洋時間 2024 年 7 月 9 日星期二上午 7:55 | 美國東部時間上午 10:55
A live webcast of the fireside chat will be available on the Investors & Media Section of Poseida's website, . A replay of the webcast will be available for approximately 90 days following the presentation.
爐邊談話的網絡直播將在波塞達網站的投資者與媒體欄目上播出。網絡直播的重播將在演講結束後約90天內播放。
About Poseida Therapeutics, Inc.
Poseida Therapeutics is a clinical-stage biopharmaceutical company advancing differentiated allogeneic cell therapies and genetic medicines with the capacity to cure certain cancers and rare diseases. The Company's pipeline includes investigational allogeneic CAR-T cell therapies for both solid tumors and hematologic cancers as well as investigational in vivo genetic medicines that address patient populations with high unmet medical need. The Company's approach is based on its proprietary genetic editing platforms, including its non-viral piggyBac DNA Delivery System, Cas-CLOVER Site-Specific Gene Editing System, Booster Molecule and nanoparticle gene delivery technologies, as well as in-house GMP cell therapy manufacturing. The Company has formed strategic collaborations with Roche and Astellas to unlock the promise of cell therapies for cancer patients. Learn more at and connect with Poseida on X and LinkedIn.
關於 Poseida Therapeutics, Inc.
Poseida Therapeutics是一家處於臨床階段的生物製藥公司，致力於推進差異化異基因細胞療法和基因藥物，能夠治癒某些癌症和罕見疾病。該公司的產品線包括用於實體瘤和血液系統癌的在研同種異體CAR-T細胞療法，以及針對未得到滿足的醫療需求的患者群體的在研活體內遺傳藥物。該公司的方法基於其專有的基因編輯平台，包括其非病毒PiggyBac DNA遞送系統、Cas-Clover特定位點基因編輯系統、增強分子和納米顆粒基因傳遞技術，以及內部GMP細胞療法制造。該公司已與羅氏和安斯泰來建立戰略合作，爲癌症患者開啓細胞療法的前景。在 X 和 LinkedIn 上了解更多，並與 Poseida 建立聯繫。
SOURCE Poseida Therapeutics, Inc.
來源 Poseida Therapeutics, Inc.
譯文內容由第三人軟體翻譯。